EFFECTS OF ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS ON AMBULATORY BLOOD PRESSURE AND CARDIOVASCULAR FUNCTION IN HYPERTENSIVE PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL DIALYSIS.

EFFECTS OF ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS ON AMBULATORY BLOOD PRESSURE AND CARDIOVASCULAR FUNCTION IN HYPERTENSIVE PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL DIALYSIS. - EFFECTS OF ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS ON AMBULATORY BLOOD PRESSURE AND CARDIOVASCULAR FUNCTION IN HYPERTENSIVE PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL DIALYSIS.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000665

Enrollment

Registered

2008-11-01

Start date

2004-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, end-stage renal disease on peritoneal dialysis

Interventions

ARB group: Start with once-daily dosing of valsartan 20-40 mg or candesartan 2-4 mg, and increase up to 80-160 mg for valsartan and 8-12 mg for candesartan, respectively, if effects of valsartan or ca

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ESRD patients with blood pressure >= 140/90 mmHg and >= 20 years old under CAPD treatment for more than six months were enrolled.

Exclusion criteria

Exclusion criteria: Malignancy, overt heart failure, acute myocardial infarction, collagen disease, acute renal failure, hyperkalemia, Pregnant women, or women suspected of being pregnant, history of hypersensitivity to valsartan or candesartan, severe hepatic disease

Design outcomes

Primary

Measure	Time frame
1) body weight, residual urinary volume. 2) casual blood pressure. 3) ambulatory blood pressure profile, blood pressure variability. 4) cardiac ultrasonography (IVSd, LVDd, LVPWd, LVDs, FS, EF(modified simpson method), E/A, DcT, etc). 5) ABI/baPWV. 6) blood parameters. CBC: Hb, Ht, fibrinogen Biochemistry: TP, Alb, BUN, s-Cr, UA, Na, K, Cl, Ca, P, GOT, GPT, Alp, T-bil, T-cho, HDL, LDL, TG, beta2-microglobulin. Endocrine: cathecholamine, PRA, PAC, ANP, BNP. Serological: CRP. 7) ECG. 8) Chest Xp. 9) Weekly erythropietin dosage.	—

Measure

Time frame

1) body weight, residual urinary volume. 2) casual blood pressure. 3) ambulatory blood pressure profile, blood pressure variability. 4) cardiac ultrasonography (IVSd, LVDd, LVPWd, LVDs, FS, EF(modified simpson method), E/A, DcT, etc). 5) ABI/baPWV. 6) blood parameters. CBC: Hb, Ht, fibrinogen Biochemistry: TP, Alb, BUN, s-Cr, UA, Na, K, Cl, Ca, P, GOT, GPT, Alp, T-bil, T-cho, HDL, LDL, TG, beta2-microglobulin. Endocrine: cathecholamine, PRA, PAC, ANP, BNP. Serological: CRP. 7) ECG. 8) Chest Xp. 9) Weekly erythropietin dosage.

—

Countries

Japan

Contacts

Public ContactKazuaki UCHINO

Yokohama City University School of Medicine Department of Medical Science

uchinok@med.yokohama-cu.ac.jp045-787-2634

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026